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Background
In recent years use of antipsychotics was widely debated
for concerns about their safety in elderly patients
affected with dementia [1,2].
Materials and methods
In order to update the use of antipsychotics in elderly
demented people, Medline research was done using the
words elderly, conventional and atypical antipsychotics,
adverse events, dementia, behavioural and psychotic
symptoms in dementia (BPSD).
Results
Conventional antipsychotics have been widely used for
BPSD; an efficacy superior to placebo was shown only at
high doses, but they were associated to several and
severe side effects [1]. Atypical antipsychotics showed an
efficacy superior to placebo in randomized studies in
BPSD treatment, with better tolerability profile vs. con-
ventional drugs [3]. However, in 2002 trials with risperi-
done and olanzapine in elderly patients affected with
dementia-related psychoses suggested a possible increase
in cerebrovascular adverse events [1]. Drug regulatory
agencies issued specific recommendations for undelining
that the treatment of BPSD with atypical antipsychotics
is “off-label” [1]. Conventional antipsychotics were
shown to be able as likely as atypical agents to increase
the risk of death among elderly persons and should not
be used to replace atypical agents discontinued after the
FDA warnings [1]. Before prescribing an antipsychotic
drug, the presence of cardiovascular diseases, QTc inter-
val on electrocardiogram, electrolytic imbalances, fami-
liar history for torsades des pointes, concomitant
treatments and use of drugs able to lengthen QTc have
to be closely taken into account. Atypical antipsychotics
are probably still the best option for short-term (6–12
weeks) treatment of aggression that is severe, persistent,
and treatment resistant, but serious adverse events are a
major contraindication to long-term therapy [4].
Conclusions
Use of atypical antipsychotics in dementia needs a care-
ful case-by-case assessment, together with the possible
drug-drug, drug-disease and drug-food interactions.
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